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j Abstract This article summarizes the results of a number of clinical
trials in the field of cardiovascular medicine which were presented during
the Hotline and Clinical Trial Update Sessions at the annual meeting of
the European Society of Cardiology, held in Munich, Germany, from 30th
August to 3rd September 2008. The data were presented by leading
experts in the field with relevant positions in the trials. It is important to
note that unpublished reports should be considered as preliminary data,
as the analysis may change in the final publications. The comprehensive
summaries have been generated from the oral presentation and the
webcasts of the European Society of Cardiology and should provide the
readers with the most comprehensive information on diagnostic and
therapeutic developments in cardiovascular medicine.
j Key words PIHRATE – HORIZONS AMI – regent – 3T/2R – AP-
PRAISE-I – SYNTAX – CARDia – IBIS II – DECREASE III – BEAUTI-
FUL – TIME-CHF – TIMIC – ONTARGET – TRANSCEND – GISSI-
HF – ATHENA – SEAS
j Abbreviations 3-VD: Three vessel disease, ACS: Acute coronary
syndrome, ACE-I: Angiotensin converting enzyme inhibitor, AF: Atrial
fibrillation, AFL: Atrial flutter, BP: Blood pressure, bpm: Beats per minute,
CABG: Coronary artery bypass grafting, CAD: Coronary artery disease, CHF:
Congestive heart failure, CI: Confidence interval, CRP: C-reactive protein,
DES: Drug eluting stents, ECG: Electrocardiogram, ESC: European Society of
Cardiology, GPIIb/IIIa: Glycoprotein IIb IIIa, HR: Hazard ratio, LDL: Low
density lipoprotein, LM: Left main coronary artery, LVEF: Left ventricular
ejection fraction, MACE: Major adverse cardiovascular events, MBG:
Myocardial blush grade, MI: Myocardial infarction, MRI: Magnetic
resonance imaging, NNT: Number needed to treat, NS: Not significant,
NSTE-ACS: Non-ST-segment elevation acute coronary syndrome, NSTEMI:
Non-ST-segment elevation myocardial infarction, NYHA: New York Heart
Association, OR: Odds ratio, PCI: Percutaneous coronary intervention, RR:
Relative risk, STEMI: ST-segment elevation myocardial infarction, STR: ST
segment elevation resolution, TVR: Target vessel revascularization, TIMI:
Thrombolysis in myocardial infarction group, UFH: Unfractionated heparin
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Acute coronary syndrome: interventions and
concomitant treatments
j Polish–Italian–Hungarian randomized
thrombectomy trial (PIHRATE trial): D. Dudek
(Krakow, Poland)
The PIHRATE trial is an international prospective
multicentre non-blinded randomized study compar-
ing thrombectomy in addition to PCI versus con-
ventional PCI (balloon predilatation followed by
direct stenting) in STEMI. The trial investigates
whether simple thrombus aspiration followed by
direct primary percutaneous coronary intervention
(PPCI) may reduce distal embolization and improve
myocardial reperfusion, because in two-thirds of
patients after conventional PPCI (stent implantation
and even with GP IIb/IIIa inhibitors) is an impaired
microcirculatory perfusion observed (MBG grade 0–
2), accompanied by partial (30%–70%) or no (<30%)
ST-segment elevation resolution (STR) in ECG)
These patients have increased early and late mor-
tality, and a higher incidence of heart failure.
Hundred and ninety six patients with STEMI <6 h
and occluded infarct related artery (TIMI grade flow
0–1) at baseline angiography were randomized to
two groups: 100 patients in the thrombectomy group
(A) and 96 patients in the control group (B) at 10
PPCI centers in Poland, Italy and Hungary. The
primary end point of the trial was STR in the ECG
after PPCI. Secondary end points included: direct
stenting rate, final TIMI grade 3 flow, corrected TIMI
Frame count (cTFC), final MBG grade 3, periproce-
dural angiographic complications, combination of
STR ‡70% and MBG 3 (optimal myocardial reper-
fusion), and in-hospital major adverse cardiac events
(MACE). Aspiration thrombectomy was successful in
91% of the cases. The study groups did not differ in
the stenting rate, stent length, or maximal stent
deployment pressure, except for the direct stenting
rate which was higher in the thrombectomy group
(75% vs. 5.2%, P < 0.0001). STR ‡70% was signifi-
cantly better in the group with thrombectomy (41.4
vs. 25.9, P = 0.037) directly after the procedure but
at 60 min after procedure, only a trend was observed
(53.7% vs. 35.1%, P = 0.29). There was no difference
in final TIMI grade 3 flow (87.8% vs. 81.3%,
P = 0.36, group A vs. group B) but the final cTFC
(28 ± 15 vs. 33 ± 19, P = 0.027) and MBG rates
(MBG grade 3, 76.1% vs. 57.8%, P = 0.026) were
significantly better in group A. Also the combined
angiographic end point of TIMI grade 3 flow + MBG
grade 3 (72.7% vs. 54.2%, P = 0.012) as well as STR
‡70% + MBG grade 3 (35.1% vs. 11.8%, P < 0.0001)
was significantly better in the thrombectomy group
but death (4.0% vs. 3.1%) and myocardial reinfarc-
tion (1.0% vs. 3.1%, P = NS) rates were similar after
6 months follow up.
In conclusion, in PIHRATE the strategy of aspira-
tion thrombectomy compared with primary PCI failed
to reduce ST-resolution 60 min after PCI in STEMI
patients presenting within 6 h after symptom onset,
although it did improve myocardial blush grade of 3.
There was no obvious benefit with clinical endpoints
at 6 months of follow-up. PIHRATE thereby confirms
the lack of impact of aspiration thrombectomy on
mortality and re-myocardial infarction. Only one
large scale trial (the TAPAS trial) demonstrated im-
proved myocardial flow and perfusion which trans-
lated into less cardiac mortality and less combined
death/re-MI.
j Impact of major adverse cardiac events and major
bleeding on overall mortality in patients with
STEMI: the HORIZONS AMI trial: R. Mehran
(New York, USA)
In HORIZONS AMI more than 3,600 patients with
STEMI (symptom onset <12 h) from 123 centers in
11 countries were randomized 1:1 to unfractionated
heparin (UFH, 60 U/kg IV), with subsequent boluses
titrated by nomogram to activated clotting time of
200–250 s, plus a GP IIb/IIIa inhibitor (abciximab or
eptifibatide), or to bivalirudin monotherapy
(0.75 mg/kg bolus; infusion 1.75 mg/kg per h),
stopped at the end of the procedure, plus provisional
GP IIb/IIIa inhibitors for large thrombus or refrac-
tory no-flow [1]. Only 7.2% of patients in the biva-
lirudin-treated group also received GP IIb/IIIa
inhibitors in the catheter laboratory. The trial was
designed to test for noninferiority and superiority of
bivalirudin compared to the UFH-GP IIb/IIIa-inhib-
itor strategy. Primary end points were net adverse
clinical events and major bleeding At 30 days biva-
lirudin monotherapy led to a 24% reduction in net
adverse clinical events and a 40% reduction in major
bleeding. MACE, defined as all-cause death, rein-
farction, ischemic target vessel revascularization
(TVR), or stroke, were no different between the two
groups (Table 1). There was no significant differ-
ences between any of the individual event rates that
made up the MACE end point, with the exception of
cardiac mortality, which was significantly reduced
in patients in the bivalirudin arm of the study
(Table 2).
To determine the impact of major bleeding and/or
MACE, the investigators developed a multivariable
Cox model with five significant baseline predictor
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variables of mortality within 30 days of presentation
with STEMI. The main event endpoints from the trial
(including the components of MACE and major
bleeding) were then added to the model as time up-
dated covariates. Within 30 days of randomization,
there were 93 deaths; 26 following a non CABG-re-
lated major bleed in 238 patients, 10 deaths following
a reinfarction in 65 patients, 9 following 82 ischemic
TVRs, and 3 following 22 strokes. In the fully adjusted
models, time updated reinfarction and non-CABG
major bleeding were significantly associated with
mortality. Ischemic TVR and stroke were not signif-
icantly associated with mortality within the first
30 days.
In conclusion, in HORIZON AMI—after
accounting for baseline predictors—both reinfarc-
tion and major bleeding have a significant impact on
mortality in the first 30 days after presenting with
STEMI. While the hazard ratio for reinfarction is
nominally higher, there are more deaths attributable
to major bleeding as compared with a reinfarction
within the first 30 days in this population. As most
drugs which reduce ischemia also increase bleeding,
the offsetting impact of adverse ischemic and hem-
orrhagic events must be carefully examined in future
trials.
j Myocardial regeneration by intracoronary infusion
of selected population of stem cells in acute
myocardial infarction (REGENT) randomized
multicenter trial: M. Tendera (Katowice, Poland)
REGENT is a multicenter, randomized trial compar-
ing the intracoronary infusion of bone marrow-de-
rived unselected mononuclear cells and selected
CD34 + CXCR4 + cells against a control group in 200
patients with acute myocardial infarction and reduced
LVEF £40%.
REGENT is after REPAIR-AMI the second-largest
trial using bone marrow-derived cells in patients with
acute MI and the first large trial for head-to-head
comparison of selected and unselected cells. The
population of CD34 + CXCR4 + cells is enriched in
cardiac committed progenitor cells, but so far, it has
not been used in a clinical trial.
Change in LVEF and volumes measured by MRI
before and 6 months after the procedure served as the
primary endpoint. In patients receiving both selected
and unselected bone marrow cells, LVEF increased
significantly in comparison to baseline values by 3%.
However, the increase in both treatment groups was
not significantly higher in comparison to the control
group. The changes in left ventricular volumes were
also comparable in all groups. Baseline LVEF was an
independent predictor of significant increase of LVEF.
At 6 months clinical follow-up, major cardiovascular
event rate was low, and no difference between the
groups was observed. Intracoronary infusion of
unselected and selected bone marrow cells proved to
be safe and feasible.
These results suggest that in patients with severely
depressed LVEF, administration of a relatively small
number of CD34 + CXCR4 + cells is safe and feasible
and can have the same effect as an infusion of a larger
number of unselected mononuclear cells. However
despite trends toward improvement of LVEF in pa-
tients with severely depressed baseline LVEF receiving
either selected or unselected bone marrow cells there
was no significance observed.
j Main results of the tailoring treatment with
tirofiban in patients showing resistance to
aspirin and/or resistance to clopidogrel study
(3T/2R): M. Valgimigli (Ferrara, Italy)
The goal of the study was to evaluate whether tir-
ofiban would reduce the incidence of MI after PCI
among poor responders to aspirin and/or clopido-
grel.
There were 263 patients enrolled in the study who
were poor responders to aspirin and/or clopidogrel,
Table 1 HORIZONS AMI trial: major outcomes
End point UFH-GP IIb/IIIa
inhibitors (%)
Bivalirudin (%) Absolute
difference (%)
Relative risk
reduction (%)
P, noninferiority P, superiority
NACE 12.1 9.2 )2.9 24 £0.0001 0.006
Major bleeding 8.3 4.9 )3.3 40 £0.0001 £0.0001
MACE 5.5 5.4 – – – NS
NACE net adverse clinical events
Table 2 HORIZONS AMI trial: death at 30 days
End point UFH-GP IIb/IIIa inhibitors (%) Bivalirudin (%) P
All death 3.1 2.1 0.058
Cardiac death 2.9 1.8 0.035
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based on point-of-care assays, who underwent elective
coronary angioplasty at ten European sites for stable
or low-risk unstable coronary artery disease. Patients
were randomly assigned in a double blind manner to
receive either a high-dose bolus tirofiban or placebo
on top of standard aspirin and clopidogrel therapy.
The primary end point was the occurrence of
periprocedural myocardial infarction, as defined by
an increase in Troponin I or T greater than three
times the upper limit of normal within 48 h. Tirofiban
reduced MACE at 30 days compared to placebo (21%
vs. 37%; P = 0.0065). There were no major bleedings
in either group.
The authors interpreted their findings as a proof of
concept for a new treatment strategy in patients with
an increased risk of thrombotic events due to non-
responsiveness of patients to standard oral antiplat-
elets such as aspirin or clopidogrel. However the
discussant criticized that the study did not use all
tests available for determining aspirin or clopidogrel
resistance and that there was no ‘‘non-resistant’’
group of patients as a control group. Since the use of
GPIIb/IIIa is already recommended in the ESC
guidelines in complex lesions as well as a pre-treat-
ment before diagnostic angiography and possible PCI
within 48 h in high risk patients, it remains to be
doubted if the study will change the already estab-
lished guidelines.
j Safety of the factor Xa inhibitor, apixaban, in
combination with antiplatelet therapy after acute
coronary syndrome: results of the APPRAISE-I dose
guiding trial: J. Alexander (Durham, USA)
APPRAISE-1 is a phase II, dose-ranging study of the
oral, direct factor Xa inhibitor, apixaban. Thousand
seven hundred and fifteen patients with recent STEMI
or NSTE-ACS were randomized to placebo (n = 611)
or one of four doses of apixaban 2.5 mg BID
(n = 317), 10 mg QD (n = 318), 10 mg BID
(n = 248), or 20 mg QD (n = 221) for 6 months. All
patients received aspirin. Use of clopidogrel was at the
discretion of the treating physician.
The primary outcome of the study was major or
clinically relevant non-major bleeding by Interna-
tional Society of Thrombosis and Hemostasis (ISTH)
criteria. Secondary outcomes were cardiovascular
death, myocardial infarction, severe recurrent ische-
mia or stroke.
The 10 mg BID and 20 mg QD apixaban arms were
discontinued early due to excess bleeding. Results
from the placebo and the two lower dose apixaban
arms were presented.
In comparism to placebo (3.0%), apixaban 2.5 mg
BID showed a trend (5.7%, HR 1.78, 95% CI 0.91–3.48,
P = 0.09) towards a dose dependent increase in ISTH
major or clinically relevant non-major bleeding,
whereas apixaban 10 mg QD reached this primary
outcome in a significant manner (7.9%, HR 2.45, 95%
CI 1.31–4.61, P = 0.005). Additionally, both evaluated
doses of apixaban resulted in non-signifcant trends
(2.5 mg BID: 7.6%, HR 0.73, 95% CI 0.44–1.19,
P = 0.21; 10 mg QD: 6.0%, HR 0.61, 95% CI 0.35–1.04,
P = 0.07) toward a reduction in clinically important
recurrent ischemic events compared to placebo
especially in patients not taking clopidgrel.
In conclusion it was discussed that it remains un-
clear what the net clinical effect of apixaban on top of
aspirin or clopidogrel is since the adverse effects
regarding bleeding risk have to be weighted against
the trend towards a clinical benefit concerning
reduction of ischemic events.
j The synergy between percutanous coronary
intervention and cardiac surgery (SYNTAX) study:
P. Serruys (Rotterdam, The Netherlands) and
W. Mohr (Leipzig, Germany)
Since interventional revascularization strategies have
experienced major developments during the last
years, PCI with DES is challenging CABG as the gold
standard for treatment of three-vessel and left main
coronary disease. Conducted at 62 European sites and
23 sites in the US the Syntax trial is the first ran-
domised controlled clinical trial to compare PCI using
drug-eluting stents (TAXUS) to coronary artery by-
pass grafting (CABG) in patients with left main (LM)
or/and three vessel disease (3-VD). The leading
hypothesis of the trial was that DES-PCI would be
non-inferior to CABG in the management of patients
with 3-vessel disease and/or left main disease.
All patients were assessed by a local multidisci-
plinary team including interventional cardiologists
and cardiac surgeons. If both, the cardiologist and the
surgeon felt they could offer revascularisation (if the
anatomy was suitable for both CABG and PCI), pa-
tients were randomized in a 1:1 fashion to PCI or
CABG. The trial randomized 1,800 patients to either
CABG (n = 897) or PCI (n = 903) with the Taxus
DES, with a primary end point of 12-month major
adverse cardiac and cerebrovascular events (MACCE),
defined as all-cause death, cerebrovascular event, MI
and repeat revascularization (PCI and/or CABG).
Secondary outcome measures included overall MAC-
CE at different follow-up periods, rates of individual
end points and quality-of-life and cost-effectiveness
measures. Due to the ‘‘all comers’’ study design pa-
tients who were ineligible for either CABG or PCI
were entered into one of two registries: 1,077 into the
CABG registry and 198 into the PCI registry.
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The incidence of the primary endpoint of major
adverse cardiac and cerebrovascular events (MACCE)
at 12 months was lower in the CABG arm compared
with PCI (12.1% vs. 17.8%, P = 0.0015), and did not
meet the prespecified non-inferiority threshold for
PCI. This was driven predominantly by a significant
reduction in the incidence of repeat revascularization
in the CABG arm compared with PCI (5.9% vs. 13.7%,
P = 0.0001). There was no difference in the incidence
of death (P > 0.05) or MI between the two arms
(P = 0.11). The incidence of cerebrovascular accident
was significantly higher in the CABG arm (2.2% vs.
0.6%, P = 0.003), whereas the incidence of symp-
tomatic graft occlusion and stent thrombosis was
similar between the two arms (3.4% vs. 3.3%,
P = 0.89) (Table 3).
In a subgroup analysis of the LM patients, the
overall 12-month MACCE event rate was similar in
CABG and PCI (13.7% vs. 15.8%), although patients
with LM only (8.5% vs. 7.1%) and LM + 1-VD (13.2%
vs. 7.5%) seemed to do slightly better with PCI. Pa-
tients with LM + 2-VD (14.4% vs. 19.8%), LM + 3-
VD (15.4% vs. 19.4%), or 3-VD alone (11.5% vs.
19.2%) seemed to do better with CABG than PCI.
When stratified by diabetes status, patients with dia-
betes had lower 12-month MACCE event rates with
CABG than with PCI (14.2% vs. 26.0%, P = 0.0025).
Non-diabetic patients showed a trend toward a benefit
with CABG but it was not statistically significant
(11.8% vs. 15.1%, P = 0.08).
In conclusion the trial demonstrates that in pa-
tients with LM disease and/or severe 3-VD, CABG
(with the use of at least one arterial graft) appears to
be superior to PCI with TAXUS DES. This is the case
for reducing 12-month MACCE rates, which were
predominantly driven by the need for repeat revas-
cularization in the PCI arm. CABG is, however,
associated with a higher risk of CVA at 12 months,
compared with PCI. Importantly, there is no differ-
ence in the incidence of death, MI, or graft occlusion/
stent thrombosis between the two arms. The largest
benefit from CABG seems to be in patients with dia-
betes mellitus. The results of this trial also suggest
that patients with LM only, LM + 1-VD, and nondi-
abetics may do as well with both CABG and PCI, al-
though the trial was not powered to study these
differences in these subgroups. With respect to those
patients included in the registries the authors con-
cluded that in patients who are not eligible for PCI,
CABG represents an option and, at least in patients
not eligible for CABG, they described PCI as a ‘‘via-
ble’’ option.
j Coronary artery revascularization in diabetes. The
CARDia trial: A. Kapur (London, Great Britain)
Since the BARI trial had suggested that CABG im-
proves survival in patients with diabetes compared to
angioplasty, this finding has guided practice. There-
fore the CARDia trial was designed to test the
hypothesis that optimal PCI is not inferior to modern
CABG as a revascularisation strategy. Five hundred
and ten patients with diabetes and multivessel or
complex single vessel disease were randomised to PCI
or CABG.
Results after 1 year showed no apparent difference
between CABG and PCI in terms of the composite
endpoints of death, non fatal MI and non fatal stroke
(10.2% vs. 11.6%, P = 0.63). Comparison of the
individual endpoints of CABG versus PCI showed also
no significant difference for death (3.3% vs. 3.2%,
P = 0.83), non fatal MI (5.7% vs. 8.4%, P = 0.25) and
non fatal stroke (2.5% vs. 0.4%, P = 0.09). As ex-
pected repeat revascularisation was significantly
higher in the PCI group with a rate of 9.9% versus
2.0% for CABG. Subgroup analysis comparing CABG
and 179 PCI patients who received drug eluting Cy-
pher stents rather than bare metal stents, showed no
difference in the composite endpoint of death, non
fatal MI and non fatal stroke (10.2% vs. 10.1%;
P = 0.98). The results of the CARDia trial indicate
that diabetic patients with 3-VD or complex 1-VD, but
not LM disease, have a similar incidence of death, MI,
or stroke at 12 months with either PCI or CABG.
However, a higher incidence of repeat revasculariza-
tion with PCI is found in these patients, even with
DES. There is also a higher incidence of stroke in the
CABG arm compared with PCI. One of the limitations
of this trial is that it may be underpowered to study
differences between the two arms, since the event
rates used for sample size calculations were signifi-
cantly different from those observed in the study.
Even so, the results of this trial are similar to the
SYNTAX trial, which demonstrated better outcomes
in diabetic patients with LM disease and/or 3-VD,
primarily due to a reduction in the incidence of repeat
revascularization.
Long-term follow-up data of the CARDia trial are
awaited to assess the durability of these results.
Table 3 SYNTAX trial
End point CABG (%) DES (%) P
MACCE 12.1 17.8 0.0015
Death/MI/stroke 7.7 7.6 0.98
Revascularization 5.9 13.7 <0.0001
Stroke 2.2 0.6 0.003
MI 3.2 4.8 0.11
All-cause death 3.5 4.3 0.37
Primary endpoint occurrence with CABG vsersus DES-PCI
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j Effects of the direct lipoprotein-associated
phospholipase A2 inhibitor darapladib on human
coronary atherosclerotic plaque: W. Wijns
(Aalst, Belgium)
The IBIS II investigators presented a randomized
phase II exploratory study on 330 patients examining
the effect of Lp-PLA2 inhibition with darapladib
(160 mg daily) after 12 months [2].
Background of the study was that lipoprotein-
associated phospholipase A2 (Lp-PLA2) is expressed
abundantly in the necrotic core of coronary lesions,
and products of its enzymatic activity may contribute
to inflammation and cell death, rendering plaque
vulnerable to rupture.
The study population were patients of at least
18 years of age undergoing catheterization for stable
coronary artery disease or an acute coronary syn-
drome. Background therapy was comparable between
groups, with no difference in low-density lipoprotein
cholesterol at 12 months. In contrast, Lp-PLA2 activ-
ity was significantly inhibited by 59% with darapladib
(P < 0.001 vs. placebo). MACE were similar between
the groups.
Concerning the two primary endpoints plaque
deformability (measured by intravascular ultrasound
palpography) and reduction of high sensitivity C-
reactive protein (hs-CRP), there were no significant
differences between darapladib-treated patients and
the control group after 12 months (both P = 0.22). In
the placebo-treated group, however, necrotic core
volume—a secondary endpoint of the study increased
significantly (4.5 ± 17.9 mm3; P = 0.009), whereas
darapladib halted this increase ()0.5 ± 13.9 mm3;
P = 0.71), resulting in a significant treatment differ-
ence of )5.2 mm3 (P = 0.012). But these intraplaque
compositional changes occurred without a significant
treatment difference in total atheroma volume
(P = 0.95).
The investigators concluded from these findings
that Lp-PLA2 inhibition may represent a novel ther-
apeutic approach. However in the discussion it was
criticized that the study did not reach the primary
endpoints and that the study design was prominently
based on intravascular ultrasound (IVUS)-oriented
nonvalidated surrogate end points rather than on
better validated surrogate end points, such as carotid
intima-media thickness, flow-mediated dilation, or
coronary plaque volume, which are known to be
better correlated with clinical end points.
j Fluvastatin XL use is associated with improved
cardiac outcome after major vascular surgery.
Results from a randomized placebo controlled
trial: DECREASE III: D. Poldermans (Rotterdam,
The Netherlands)
In patients undergoing non-cardiac vascular surgery
perioperative cardiac events are the major cause of
adverse outcome. Recent retrospective studies sug-
gested a potential beneficial role of statins in the
prevention of perioperative myocardial infarction. In
the prospective, randomized, placebo controlled DE-
CREASE III study 497 statin-naive patients scheduled
to undergo vascular surgery were randomized to a
sustained-release formulation of fluvastatin (n = 250)
80 mg per day or placebo (n = 247) an average of
37 days prior to surgery. The statin was continued for
at least the first 30 days after surgery. The primary
end point was myocardial ischemia, as assessed by a
combination of continuous ECG monitoring in the
first 72 h, intermittent troponin-T measurements and
further ECGs until the end of follow-up on day 30.
Myocardial ischemia was detected in 74 (14.9%) pa-
tients within 30 days of the initial vascular surgical
procedure. A total of 27/250 (10.9%) patients allo-
cated to fluvastatin reached the primary endpoint
compared to 47/247 (18.9%) patients allocated to
placebo treatment (OR 0.53; 95% CI 0.32–0.88).
Hence, NNT to prevent one patient experiencing
myocardial ischemia was 12.5 patients. A total of 18
(3.6%) patients died within 30 days after surgery of
which 12 (2.4%) were attributable to cardiovascular
causes. Additionally, 25 (5.0%) patients experienced a
nonfatal myocardial infarction within 30 days after
surgery. The combined endpoint of cardiovascular
death and nonfatal myocardial infarction was reached
in 37/497 (7.4%) patients. A total of 12/250 (4.8%)
patients allocated to fluvastatin therapy reached the
combined endpoint, compared to 25/247 (10.1%)
allocated to placebo. Hence, fluvastatin therapy was
associated with a 52% relative reduction in the inci-
dence of cardiovascular death or MI (OR 0.48; 95% CI
0.24–0.95) (Table 4). The NNT for the composite
endpoint of cardiovascular death or nonfatal MI is
18.9 patients. In addition to clinical endpoints the
effect of statin treatment on inflammatory markers
such as interleukin-6 (IL-6) and CRP was assessed. IL-
Table 4 DECREASE III trial
Outcome Odds
ratio
95% CI Absolute risk
reduction (%)
NNT
Myocardial ischemia 0.53 0.32–0.88 )8.0 13
Nonfatal MI 0.55 0.24–1.27 )2.8 36
Cardiovascular death 0.33 0.09–1.22 )2.4 42
CV death or nonfatal MI 0.48 0.24–0.95 )5.3 19
Odds ratios for primary and secondary outcomes (statin patients compared with
placebo)
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6 levels (5.75 vs. 8.45 pg/ml, P < 0.001) and CRP (4.66
vs. 6.00 mg/l, P £ 0.001) were significantly reduced in
the fluvastatin-group compared with placebo.
In conclusion, fluvastatin seems a safe choice to
improve perioperative outcome in CABG. It remains
to be examined if this is a specific fluvastatin effect or
rather a group effects of the statins.
Heart failure
j Morbidity–mortality evaluation of the If inhibitor
ivabradine in patients with coronary artery disease
and left ventricular dysfunction (BEAUTIFUL):
K. Fox (Brompton Hospital, UK)
Ivabradine is a specific inhibitor of the I(f) current in
the sinoatrial node and therefore lowers heart rate,
without affecting other aspects of cardiac function.
The BEAUTIFUL trial aimed to test whether lowering
heart rate with ivabradine reduces cardiovascular
death and morbidity in patients with coronary artery
disease CAD and left-ventricular systolic dysfunction
(LVEF <40%).
BEAUTIFUL, a randomised, double-blind, pla-
cebo-controlled, parallel-group trial, enrolled 10.917
patients from 781 centers in 33 countries, and ran-
domized them to 5 mg ivabradine (with the aim of
titrating up to 7.5 mg twice per day) or matched
placebo, on top of best medical therapy (including
high rates of aspirin, ACE-I, and beta blockers).
Eighty seven percent of the patients received beta-
blockers in addition to study drugs. The primary
endpoint was a composite of cardiovascular death,
admission to hospital for acute myocardial infarction,
and admission to hospital for new onset or worsening
heart failure. The mean heart rate at baseline was
71.6 ± 9.9 bpm. At a median of 19 months of follow-
up, ivabradine reduced heart rate by 6 ± 0.2 bpm but
did not affect the primary composite end point
(hazard ratio 1.00, 95% CI 0.91–1.1, P = 0.94) [3] In a
subanalysis of the placebo group, the BEAUTIFUL
investigators demonstrated—as expected [4] but
never proven—that elevated resting heart rate at
baseline is a marker for subsequent cardiovascular
death and morbidity, as patients with heart rates of
70 bpm or greater had increased risk for cardiovas-
cular death (34%, P = 0.0041), admission to hospital
for heart failure (53%, P < 0.0001), admission to
hospital for myocardial infarction (46%, P = 0.0066),
and coronary revascularisation (38%, P = 0.037) [5]
(Table 5). Nevertheless, even in a prespecified sub-
group of patients with heart rate of ‡70 bpm, ivabr-
adine had no effect on the primary composite
outcome (HR 0.91, 95% CI 0.81–1.04, P = 0.17). It did,
however, reduce secondary endpoints such as
admission to hospital for fatal and non-fatal myo-
cardial infarction (HR 0.64, 95% CI 0.49–0.84,
P = 0.001) and coronary revascularisation (HR 0.70,
95% CI 0.52–0.93, P = 0.016), even on top of beta-
blocker therapy [3]. These data on secondary end-
points should be interpreted with caution since the
results may be confounded by the fact that the use of
beta-blockers was slightly higher in the group with
heart rates lower than 70 bpm (90% vs. 84%), which
may account for the larger effect of ivabradine among
the patients with higher heart rates. Secondly, the
large number of secondary endpoints in BEAUTIFUL
bears the risk of false-positive results in subgroup
analyses. Therefore, the data regarding secondary
endpoints warrant careful statistical analysis before
any formal conclusions can be drawn.
In summary, ivabradine appears to safely lower
heart rate, but while doing so has no effect on cardiac
death, need for PCI, or admission to the hospital for
heart failure or MI in patients with stable CAD and LV
dysfunction. Nevertheless, it may be useful to reduce
the incidence of CAD outcomes in a subgroup of
patients who have heart rates ‡70 bpm. At present,
beta-blockers remain the first choice to lower heart
rate in patients with heart failure, but ivabradine is
likely to become a valuable alternative in patients who
do not tolerate beta-blocker therapy. Additional
information on the role of ivabradine in CHF patients
will be provided by the SHIFT trial [6].
j Trial of intensified (BNP-guided) versus standard
(symptom-guided) medical therapy in elderly
patients with congestive heart failure: TIME-CHF:
HP. Brunner-La Rocca (Basel, Switzerland)
The TIME-CHF study was designed to evaluate the
medical management of very old patients (‡75 years)
with CHF compared with younger patients (60–
74 years) (Table 6), and to compare an intensified
with a standard treatment approach. The rationale
behind the study was the fact that the group of pa-
tients older than 75 years has been greatly under-
represented in clinical CHF trials, and that the
evidence on which the current guidelines are based,
Table 5 BEAUTIFUL trial
End point Hazard ratio P
Cardiovascular death 1.34 0.0041
Admission for heart failure 1.53 <0.0001
Admission for MI 1.46 0.0066
Coronary revascularization 1.38 0.037
Adjusted hazard ratios for heart rate >70 versus <70 bpm
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does not adequately represent this patient population
[7].
In TIME-CHF, a prospective single-blinded multi-
center trial, 499 patients with symptomatic heart
failure (‡NYHA class 2; LVEF £45%) despite medical
treatment who had been hospitalized for CHF within
the previous year and had an elevated N-terminal
brain-type natriuretic peptide level (NT-proBNP;
‡twice the upper limit of normal), were randomized
to natriuretic-peptide-guided or symptom-guided
management. Medical treatment strategies followed
the European guidelines (including ACE-I, AT1
receptor blockers, beta-blockers, and, for patients in
NYHA class 3 or worse, spironolactone or eplere-
none) with the aim to reduce symptoms to NYHA
class £2 (standard) or, additionally, NT-proBNP levels
below 400 pg/ml for patients aged 60–74 years or
below 800 pg/ml for those ‡75 years (intensified). The
primary study end point was hospitalization-free
survival at 18 months. Independently of the patient’s
age, ‘‘intensified’’ therapy guided by NT-proBNP
levels led to higher dosages of ACE-I, beta blockers,
and other standard CHF medications. Both NT-
proBNP-guided therapy and standard management
significantly reduced NT-proBNP levels from baseline
to 6 months to a similar degree. Overall, the HR (95%
CI) of standard therapy vs. natriuretic peptide-guided
therapy for the primary end point, 18-month survival
free of any hospitalization, was 0.92 (0.73–1.15).
Hence, the use of natriuretic-peptide levels rather
than symptoms alone to guide medical treatment of
CHF failed to influence the primary end point of
hospitalization-free survival. The natriuretic-peptide-
based approach did however improve survival free
from CHF hospitalizations, a secondary end point,
among the prospectively defined subgroup of patients
<75 years. In contrast, patients ‡75 years did not
show any outcome difference between the two man-
agement strategies. Interestingly, the improvements
in quality-of-life scores were less pronounced on
intensified therapy as compared to standard symp-
tom-guided management in the older patients
(P < 0.05), whereas they were similar in the younger
patients. This finding indicates that intensified med-
ical therapy may cause some harm in the elderly pa-
tients who tend to have more co-morbidities than
younger patients.
The study indicates that CHF patients ‡75 years
respond differently to heart failure therapies com-
pared with younger patients, and furthermore sug-
gests that lessons from the CHF trials on which
treatment guidelines are based may not apply to
elderly patients with heart failure. As a result, clin-
ical CHF trials targeting older patients are war-
ranted.
j Randomized study on the efficacy of
immunosuppressive therapy in patients with
virus-negative inflammatory cardiomyopathy:
A. Frustaci (Rome, Italy)
There is currently no consensus on the management
of patients with chronic inflammatory dilated car-
diomyopathy, other than the use of standard heart
failure medications. The role of immunosuppressive
therapy in these patients, both pediatric and adult,
remains controversial. The goal of the single center
randomized TIMIC-trial was to evaluate the efficacy
of immunosuppressive therapy in adult patients with
virus-negative inflammatory cardiomyopathy.
Patients with inflammatory cardiomyopathy who
were unresponsive to standard heart failure therapy
and were virus negative received either immunosup-
pressive therapy with prednisone (1 mg/kg daily for
1 month, followed by 0.33 mg/kg daily for 5 months),
and azathioprine (2 mg/kg daily for 6 months), or
matching placebo. Eighty five patients were random-
ized, 43 to the immunosuppressive therapy arm, and
42 to the placebo arm. There were no significant
differences in the baseline characteristics between the
two groups. The mean LV ejection fraction at baseline
was 27.1 ± 6.5%, and most patients with NYHA class
III or IV symptoms. Diagnostic angiography, biven-
tricular angiography at baseline, and endomyocardial
biopsy at baseline, 1 month, and 6 months were
performed in all patients.
There was a significant improvement in the LVEF
in the immunosuppressive therapy arm compared
with placebo at 6 months: 88% of the patients in the
treatment arm showed an improvement in LVEF
(26.4 ± 6.9–48.0 ± 7.3%) and LV end-diastolic diam-
eter (LVEDD) (68.6 ± 7.4–52.8 ± 6.3 mm). None of
the patients in the placebo arm improved, with
even 83% of the patients deteriorating regarding
LVEF (27.6 ± 6.6–19.5 ± 4.8%) and LV dilatation
(69.2 ± 7.9–75.3 ± 7.4).
Table 6 TIME-CHF trial
Feature Age 60–74
n = 210
Age >75
n = 289
P
Mean age (year) 69 89 <0.001
Female (%) 25 41 <0.001
CAD heart-failure etiology (%) 49 64 <0.001
LVEF (%) 28 10 <0.001
NYHA class ‡3 (%) 66 81 <0.001
‡2 comorbidities (%) 64 79 <0.001
Creatinine (lm/l) 111 121 0.004
Baseline differences between the younger (age 64–74 years) and elderly (age
>75 years) patient groups
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In the immunosuppressive therapy arm, endo-
myocardial biopsy showed an improvement in
inflammation, with disappearance of inflammatory
infiltrates in patients who were classified as
responders and in reduction or disappearance of
inflammation with degeneration of myocytes in pa-
tients regarded as nonresponders. However, in biop-
sies of the placebo arm persistent myocardial
inflammation and cell necrosis, with expansion of
fibrosis, were detected.
The authors see their trial as the first randomized
study in patients with proof of persistent inflamma-
tion and virus negative inflammatory cardiomyopathy
in whom immunosuppression proved to be effective.
However, they so far presented only changes in LVEF
and LVEDD, while clinical outcomes remain to be
determined. Larger multicenter studies are needed to
confirm these interesting findings, since this could
represent a novel approach to the management of
heart failure in virus negative inflammatory cardio-
myopathy.
j Blood pressure analyses from 25,595 patients (from
25,620 randomised) during the ONTARGET trial:
reflections on current guidelines: P. Sleight
(Oxford, Great Britain)
The ONTARGET trial showed that telmisartan (80 mg
per day) was ‘‘noninferior’’ to ramipril (10 mg per
day) in 25,260 patients with coronary heart disease or
diabetes plus additional risk factors who were over
the age of 55 years of age but did not have evidence of
heart failure [8].
The combination of the two drugs was associated
with more adverse events without an increase in
benefit. In a new observational analysis of the ON-
TARGET study the 25,260 patients were divided into
four quartiles based upon blood pressure, regardless
of which study arm they had been randomized to. The
analysis showed that only the very highest quartile of
BP (systolic BP >154 mm Hg) had a significantly
higher risk of the primary end point: cardiovascular
death, stroke, MI, or heart-failure hospitalization
(P < 0.001). When the end points were considered
separately, there were no differences between the four
BP quartiles for cardiovascular death or for MI. But
those patients in the lowest quartile of BP (systolic
£130 mm Hg) had significantly less risk of stroke
than those in the highest quartile.
The investigators also reported about evidence of
potential harm among diabetics: although those with
diabetes in the highest quartile of blood pressure did
have a higher risk of the primary outcome, when it
came to cardiovascular death alone, those in the
lowest quartile had an increased risk of death. The
presenter suggested from these results, that in high
risk people the guidelines of lowering blood pressure
as much as possible may not apply.
j Telmisartan randomized assessment study in
ACE-intolerant subjects with cardiovascular disease
(TRANSCEND): K.K. Teo (Hamilton, ON, Canada)
Angiotensin-converting enzyme (ACE) inhibitors
reduce mortality and major cardiovascular events in
patients with cardiovascular disease or high-risk
diabetes, but are not tolerated by about 20% of pa-
tients, mainly due to cough but also due to hypo-
tension, renal dysfunction, or angioneurotic edema.
Angiotensin-receptor blockers (ARB) may be a
valuable alternative in patients with or without heart
failure that are intolerant to ACE inhibitors. Fur-
thermore, some studies suggest that the combination
of ACE inhibitors and ARBs is superior to their
single use. Recently, the ONTARGET trial, that was
designed as the biggest comparison to date of ARB
and ACE-inhibitor therapy or their combination in
high-risk patients (>55 years, coronary heart disease,
peripheral artery disease, cerebrovascular disease,
diabetes with endorgan damage) with controlled
blood pressure and without evidence of heart failure,
showed that the ARB telmisartan was noninferior to
the ACE inhibitor ramipril in terms of blood-pres-
sure-independent cardioprotection, and that the
combination of the two did not offer any additional
benefit [8, 9].
TRANSCEND, a sibling study to ONTARGET, was
designed to assess whether the ARB telmisartan
would be effective in high-risk patients with car-
diovascular disease or diabetes with end-organ
damage that are unable to tolerate ACE inhibitors.
After a 3-week run-in period, 5,926 patients
>55 years with coronary heart disease, peripheral
artery disease, cerebrovascular disease, or high-risk
diabetes without evidence of heart failure who were
intolerant to ACE inhibitors were randomised to
receive telmisartan 80 mg/day or placebo, in addi-
tion to other usual therapies. Compared with similar
trials, the patient population in TRANSCEND had
more women, more patients with a history of stroke,
and more with hypertension [10]. The primary out-
come was the composite of cardiovascular death,
myocardial infarction, stroke, or hospitalization for
heart failure. Mean blood pressure was, on average,
4 mmHg lower in the telmisartan group than in the
placebo group throughout the study. After a median
follow-up of 56 months, there was no difference in
the composite primary end point, which occurred in
465 (15.7%) of patients taking telmisartan and 504
(17.0%) of those on placebo (HR 0.92; P = 0.216).
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One of the prespecified secondary outcomes, a
composite of cardiovascular death, myocardial
infarction, or stroke, occurred in 384 (13.0%) pa-
tients on telmisartan compared with 440 (14.8%) on
placebo (HR 0.87, P = 0.048). Eight hundred and
ninety four (30.3%) patients receiving telmisartan
were hospitalized for a cardiovascular reason, com-
pared with 980 (33.0%) on placebo (RR 0.92;
P = 0.025). One important aspect is that fewer pa-
tients discontinued study medication in the telmi-
sartan group than in the placebo group, indicating
that telmisartan was well tolerated in patients unable
to tolerate ACE inhibitors. In summary, telmisartan
had no significant effect on the primary endpoint of
the study, and the preventive effect of the drug
regarding cardiovascular death, myocardial infarc-
tion, or stroke, is modest at best.
The failure of telmisartan to reach the primary
endpoint in TRANSCEND is rather surpising, partic-
ularly in light of the previous findings with ACE
inhibitors from the HOPE, PEACE, and EUROPA
trials. There are several potential explanations for the
negative result of TRANSCEND that include a possi-
ble heterogeneity in the ARB class, but also the fact
that TRANSCEND was ambitiously powered to find a
19% relative risk reduction [11]. A combined, time-
stratified analyses of TRANSCEND and PRoFESS [12]
comparing telmisartan with placebo on outcome of
cardiovascular death, myocardial infarction, stroke,
and hospitalization for heart failure, showed no effect
of telmisartan in the first 6 months, but a clear benefit
after 6 months. These analyses suggest that there may
be a delay of six to 12 months before the benefits of
ARBs emerge. Based on ONTARGET and TRAN-
SCEND, it seems reasonable that if the HOPE criteria
apply, telmisartan or other ARBs may be used as an
alternative to ACE inhibitors. The mechanisms be-
hind the lack of effects on prevention of heart failure
remain unknown. Therefore additional data are nee-
ded on ARBs, particularly in broader high-risk pop-
ulations.
j Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico Heart Failure (GISSI-HF):
effect of n-3 polyunsaturated fatty acids in
patients with chronic heart failure: L. Tavazzi
(Pavia, Italy)
Several epidemiological and experimental studies
suggest that n-3 polyunsaturated fatty acids (PUFA)
can exert favorable effects on atherothrombotic car-
diovascular disease, including arrhythmias. GISSI-HF
is a large-scale, randomized, double-blind, placebo-
controlled study program consisting of two nested
studies that were designed to investigate the effects of
omega-3 fatty acids on one hand and statin therapy
on the other hand on mortality and morbidity in
patients with symptomatic heart failure.
In the PUFA study, investigators from 357 centers
enrolled a total of 6,975 patients with CHF (NYHA
class 2-4 irrespective of cause and LVEF), and ran-
domized them to treatment with n-3 PUFA 1 g daily
or placebo. Patients were followed up for a median of
3.9 years. The primary study endpoints were time to
death, and time to death or admission to hospital for
cardiovascular reasons. After 3.9 years of follow-up,
treatment with the omega-3 fatty acids reduced the
RR of mortality by 9% and the RR of mortality and
admission to the hospital for cardiovascular causes by
8% [13]. In absolute numbers, 955 (27.3%) patients
died from any cause in the n-3 PUFA group and 1,014
(29.1%) in the placebo group (adjusted HR 0.91
[95.5% CI 0.833–0.998], P = 0.041). Thousand nine
hundred and eighty one (56.7%) patients in the n-3
PUFA group and 2,053 (59.0%) in the placebo group
died or were admitted to hospital for cardiovascular
reasons (adjusted HR 0.92 [99% CI 0.849–0.999],
P = 0.009) (Table 7). There was no difference in the
frequency of gastrointestinal disorders, representing
the most common adverse reaction in both treatment
groups [96 (3%) n-3 PUFA group vs. 92 (3%) placebo
group]. While the absolute risk reduction for mor-
tality was only 1.8%, the number-needed-to-treat in
Table 7 GISSI-HF trial
End point Omega-3 fatty acids
n = 3, 494 (%)
Placebo
n = 3,481 (%)
Adjusted hazard
ratio (95% CI)
Primary end points
Mortality 27.3 29.1 0.91 (0.833–0.998)
All-cause mortality or hospitalization for
cardiovascular causes
56.7 59.0 0.92 (0.849–0.999)
Secondary end points
Death from cardiovascular causes 20.4 22.0 0.90 (0.81–0.99)
Sudden cardiac death 8.8 9.3 0.93 (0.79–1.08)
Patients admitted for cardiovascular causes 46.8 48.5 0.93 (0.87–0.99)
Patients with fatal and nonfatal MI 3.1 3.7 0.82 (0.63–1.06)
Patients with fatal and nonfatal stroke 3.5 3.0 1.16 (0.91–1.53)
Omega-3 fatty acid study: results of primary and secondary endpoints
860 Clinical Research in Cardiology, Volume 97, Number 12 (2008)
 Steinkopff Verlag 2008
order to avoid one death during the median follow-up
of 3.9 years was 56, and the NNT to avoid one event
like death or admission to hospital for cardiovascular
reasons was 44. A per-protocol analysis that included
only patients who remained on treatment for the
study duration confirmed the overall findings, show-
ing that treatment cut the absolute risk by 3.3%
compared with placebo, corresponding to a 14% RR
reduction. Although the overall benefit in patients
with CHF was only modest, it should be noted that it
was obtained in a population already treated with
recommended therapies, and was consistent across all
predefined subgroups.
Although the exact mechanisms of action remain
unknown, omega-3 fatty acids could possibly exert
favorable effects on inflammatory processes, such as
reductions in endothelial activation and cytokine
production, as well as influence platelet aggregation,
blood pressure, heart rate, ventricular function, and
autonomic tone. When compared to the GISSI Pre-
venzione trial [14, 15], in which n-3 PUFA supple-
mentation reduced mortality by 21% in patients with
MI mainly by influencing the risk of sudden death,
this risk was not significantly different between the
treated and untreated patients in GISSI-HF, suggest-
ing that n-3 PUFA may act beneficially in heart-failure
patients by other mechanisms of action than in post-
MI patients. Although questions remain about the
mechanism of action, optimum dosing and formula-
tion, supplementation with n-3 PUFA can provide a
small beneficial advantage in terms of mortality and
admission to hospital for cardiovascular reasons in
CHF patients and therefore joins the short list of
evidence-based life-prolonging therapies for heart
failure [16].
j Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico Heart Failure (GISSI-HF):
effect of rosuvastatin in patients with chronic heart
failure: Gianni Tognoni (Milan, Italy)
Large observational studies, small prospective studies
and post-hoc analyses of randomized clinical trials
have suggested that HMG-CoA reductase inhibitors
(statins) may exert beneficial effects in patients with
CHF [17]. While these previous studies have been
methodologically weak, the safety and efficacy of
rosuvastatin in patients with heart failure have now
been investigated in two placebo-controlled, ran-
domized trials, the ‘‘Controlled Rosuvastatin in Mul-
tinational Trial in Heart Failure’’ (CORONA) [18],
and the statin part of GISSI-HF [19].
Similar to the n-3 PUFA part of GISSI-HF (see
above), the complementary study focussing on the
effects of rosuvastatin was a randomised, double-
blind, placebo-controlled trial that was conducted in
357 centers. Four thousand five hundred and seventy
four patients with chronic heart failure (NYHA class
2–4, irrespective of cause and LVEF) were enrolled
and randomly assigned to rosuvastatin 10 mg or
placebo. The primary endpoints were time to death,
and time to death or admission to hospital for car-
diovascular reasons. Treatment with rosuvastatin
sufficiently decreased LDL cholesterol levels by 27%
at 3 years from 123 mg/dl at baseline to 90 mg/dl,
and furthermore significantly decreased high-sensi-
tivity C-reactive protein (CRP) levels. However, while
omega-3 fatty-acid supplementation improved the
morbidity and mortality in symptomatic heart failure
patients in GISSI-HF, rosuvastatin failed to have any
beneficial effect in the same group of patients. After
a mean follow-up of 3.9 years, there was no signifi-
cant difference between the treatment arms in either
of the two co-primary end points: 657 (29%) patients
died from any cause in the rosuvastatin group and
644 (28%) in the placebo group [adjusted HR 1.00
(95.5% CI 0.90–1.12), P = 0.94]. Thousand three
hundred and five (57%) patients in the rosuvastatin
group and 1,283 (56%) in the placebo group died or
were admitted to hospital for cardiovascular reasons
[adjusted HR 1.01 (99% CI 0.91–1.11), P = 0.90]. The
findings were consistent across all secondary end
points as well as consistent across every subgroup
analyzed, including older patients, those with LVEF
>40%, and those with and without diabetes. Hence,
rosuvastatin 10 mg daily did not affect clinical out-
comes in patients with chronic heart failure of any
cause, in whom the drug was safe.
The results of the GISSI-HF study are in line with
findings from the CORONA trial. In CORONA,
treatment with rosuvastatin had no significant effect
on cardiovascular outcomes, as measured by the
primary-end-point composite of cardiovascular
death, nonfatal MI, or stroke. It did, however, sig-
nificantly reduce the number of hospitalizations from
cardiovascular causes and from heart failure [13].
Similarly, rosuvastatin did not reduce all-cause mor-
tality and admission to the hospital for cardiovascular
reasons in GISSI-HF [19], with patient’s having less
severe heart failure than in CORONA. Thus, both
CORONA and GISSI-HF (rosuvastatin) are comple-
mentary and establish that, although statin therapy
lowers the concentrations of LDL cholesterol, is well
tolerated, and seems reasonably safe, it does not
produce meaningful improvements in survival in
patients with chronic heart failure. Therefore, the
prescription of rosuvastatin or any statin to patients
with heart failure should not be considered because
the use of the cholesterol-lowering drugs does not
translate into any clinical benefit for heart failure
patients.
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Arrhythmia
j ATHENA: the effect of dronedarone on
cardiovascular outcomes and stroke in patients
with atrial fibrillation: S.J. Connolly
(Hamilton, Canada)
ATHENA is a placebo-controlled, double-blind, par-
allel arm trial to assess the efficacy of dronedarone
400 mg two times a day versus placebo for the pre-
vention of cardiovascular hospitalization or death
from any cause in patients with AF or AFL.
A total of 4,628 patients were randomized from
more than 550 sites in 37 countries: 2,301 to drone-
darone and 2,327 to placebo for a minimum treatment
and follow-up duration of 1 year.
About 42% of the patients were ages 75 years or
older. Patients were stratified based on the presence
or absence of AF or AFL at baseline, which was
present in one-quarter of the patients randomized.
Twelve percentage of the patients had evidence of
systolic dysfunction, with an ejection fraction of lower
than 45%. About 30% of the patients had coexisting
coronary artery disease. The rate of drug discontin-
uation was similar between the two arms as well as the
rate of side effects.
Patients receiving dronedarone had—compared
with placebo—a significant 24% reduction in hospi-
talizations or death due to cardiovascular causes over
a follow-up time of about 21 months (P < 0.001).
Compared with placebo, dronedarone induced a sig-
nificant reduction in the risk of cardiovascular death
by 30% (P = 0.03). This was driven primarily by a
significant 45% reduction in the incidence of death
due to arrhythmias (P = 0.01). The overall mortality
did not differ between the two arms (HR 0.84,
P = 0.18). There was a significant reduction in the
incidence of stroke in the dronedarone arm compared
with placebo (1.2% vs. 1.8%, HR 0.66, P = 0.027).
Although this trial did not directly compare dron-
edarone to amiodarone, indirect comparisons from
this trial suggest that dronedarone may be similar in
efficacy to amiodarone, without being associated with
significant side effects. It will be therefore interesting
to see the outcome of trials comparing dronedarone to
amiodarone (e.g. DIONYSOS).
Aortic stenosis
j Simvastatin plus ezetimibe in aortic stenosis: the
SEAS study: T.R. Pedersen (Oslo, Norvay)
The SEAS study is the first large-scale randomised
trial to assess the effects of lowering LDL-cholesterol
in patients with aortic stenosis. The study included
1,873 patients with mild to moderate aortic stenosis
without symptoms who were not considered to have a
clear indication for treatment with cholesterol-low-
ering drugs [20]. Patients were randomly assigned to
receive either intensive cholesterol lowering with the
combination of simvastatin (40 mg daily) and eze-
timibe (10 mg daily) or matching placebo. The pri-
mary outcome was a composite of major
cardiovascular events, including death from cardio-
vascular causes, aortic-valve replacement, nonfatal
myocardial infarction, hospitalization for unstable
angina pectoris, heart failure, coronary-artery bypass
grafting, percutaneous coronary intervention, and
nonhemorrhagic stroke. Secondary outcomes were
events related to aortic-valve stenosis and ischemic
cardiovascular events.
Compared with placebo, the combination of sim-
vastatin and ezetimibe reduced LDL-cholesterol by an
average of 61%, corresponding to a reduction of about
2 mmol/l (76 mg/dl), and this effect was sustained
throughout the study. Six hundred and eighty eight
patients had one or more primary endpoint events.
No significant difference was observed between the
treatment groups for the combined primary endpoint
nor for the secondary endpoint of aortic valve disease
events alone. The combination of simvastatin and
ezetimibe did, however, produce a statistically sig-
nificant 22% (P = 0.02) proportional reduction in the
secondary endpoint of atherosclerotic events alone:
15.7% in the simvastatin plus ezetimibe group versus
20.1% in the placebo group.
The study therapy was generally well tolerated.
However, in the subsidiary safety analyses, a total of
175 patients were recorded with a serious adverse
event attributed to cancer. More of these events were
observed among patients assigned the combination of
simvastatin and ezetimibe than among those assigned
placebo [105 (11.1%) vs. 70 (7.5%); unadjusted
P = 0.01]. There were also slightly more cancer deaths
[39 (4.1%) vs. 23 (2.5%); unadjusted P = 0.05] (Ta-
ble 8). These apparent differences were not related to
any particular type of cancer and did not become
significantly larger with more prolonged treatment.
The discussant of the study, Eugen Braunwald,
explained, that the observed differences in cancer in
the SEAS study are based on small numbers and could
have occurred as a result of chance. In order to assess
their relevance, the SEAS data have been provided to
an independent academic group for combined anal-
ysis with data on cancer from the two other large
trials of simvastatin and ezetimibe, which are still in
progress [21]. The SHARP (Study of Heart and Renal
Protection) study is a randomized placebo-controlled
trial of simvastatin and ezetimibe in 9,400 patients
with chronic kidney disease. The IMPROVE-IT (IM-
Proved Reduction of Outcomes: Vytorin Efficacy
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International Trial) study is a randomized double-
blind trial of simvastatin and ezetimibe compared to
simvastatin alone which has recruited 12,000 of a
planned 18,000 patients with acute coronary disease.
In combination, the SHARP and IMPROVE-IT studies
involve about four times as many cancers as in the
SEAS study. Independent analysis of these data with
was initiated and has been conducted and interpreted
by the Clinical Trial Service Unit at the University of
Oxford, UK. Their analysis of SHARP and IMPROVE-
IT does so far not support the suggestion of an in-
crease in cancer that was raised by the subsidiary
analyses of the relatively small numbers of cancers in
the SEAS study [21] (Table 9). However the follow up
time of SHARP and IMPROVE-IT are at the time
being much shorter than in SEAS, so the final data
have to be carefully watched [22].
In conclusion, the SEAS study has found that
intensive LDL-cholesterol lowering with the combi-
nation of simvastatin and ezetimibe in patients with
mild to moderate aortic stenosis does appear to re-
duce the risk of coronary artery disease events (as has
been shown for many other types of patient in pre-
vious trials) but not the rate of progression of aortic
valve disease. The use of simvastatin and ezetimibe in
such patients was generally well tolerated and safe.
However due to the increase in cancer rates, the final
results of the SHARP and IMPROVE-IT trials have to
be evaluated for cancer risk and cancer death.
Table 8 SEAS: any fatal or nonfatal cancer and death from cancer (Oxford
analysis)
Value Active treatment
(n = 944)
Control
(n = 929)
P
(unadjusted)
Any fatal or nonfatal
cancer (n)
101 65 0.006
Percent per year 2.7 1.7 –
Death from any cancer
(n)
37 20 0.04
Percent per year 0.9 0.5 –
Table 9 IMPROVE-IT and SHARP: any fatal or nonfatal cancer and death from
cancer (Oxford analysis)
Value Active treatment
(n = 10,319)
Control
(n = 10,298)
P
(unadjusted)
Any fatal or nonfatal
cancer (n)
313 326 0.61
Percent per year 1.7 1.8 –
Death from any
cancer (n)
97 72 0.07
Percent per year 0.5 0.4 –
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